In the last decade, several MCHR1 antagonists were presented; some have entered clinical trials for the treatment of obesity [29] or are discussed to become anti-diabetic drugs [30]. The gene discussed is MCHR1; the disease is obesity due to melanocortin 4 receptor deficiency.